Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats

Respirology

Volumn 15, Issue 4, 2010, Pages 659-668

  Kim, Eun Kyung ^a   Lee, Ji Hyun ^a   Oh, Yeon Mock ^b   Lee, Yun Song ^c   Lee, Sang Do ^b  

^a CHA University   (South Korea)

^b University of Ulsan   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

Endothelin 1; Hypoxia; Peroxisome proliferator activated receptor gamma; Pulmonary arterial hypertension; Rosiglitazone

Indexed keywords

ENDOTHELIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; VASCULOTROPIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG INHIBITION; HYPOXIA; IMMUNOHISTOCHEMISTRY; INSPIRATORY RESERVE VOLUME; LONG TERM CARE; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; AGONISTS; ANIMAL; ANOXIA; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HYPERTENSION, PULMONARY; PATHOLOGY; PULMONARY ARTERY; SPRAGUE DAWLEY RAT;

ANIMALS; ANOXIA; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; HYPERTENSION, PULMONARY; MALE; PPAR GAMMA; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77951725877     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01756.x     Document Type: Article

References (40)

1. Pierson DJ. Pathophysiology and clinical effects of chronic hypoxia. Respir. Care 2000 45 : 39 51.
2. Rabinovitch M, Gamble W, Nadas AS et al. Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am. J. Physiol. 1979 236 : H818 27.
3. Haffner SM, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002 106 : 679 684.
4. Law RE, Meehan WP, Xi XP et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest. 1996 98 : 1897 1905.
5. de Dios ST, Bruemmer D, Dilley RJ et al. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003 107 : 2548 2550.
6. Calnek DS, Mazzella L, Roser S et al. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2003 23 : 52 7.
7. Yamakawa K, Hosoi M, Koyama H et al. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 2000 271 : 571 574.
8. Emoto M, Anno T, Sato Y et al. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes 2001 50 : 1166 1170.
9. Satoh H, Tsukamoto K, Hashimoto Y et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPAR-g on vascular endothelial function. Biochem. Biophys. Res. Commun. 1999 264 : 757 763.
10. Delerive P, Martin-Nizard F, Chinetti G et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res. 1999 85 : 394 402.
11. Iglarz M, Touyz RM, Amiri F et al. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler. Thromb. Vasc. Biol. 2003 23 : 45 51.
12. Ameshima S, Golpon H, Cool CD et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ. Res. 2003 92 : 1162 1169.
13. Girgis RE, Li D, Zhan X et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am. J. Physiol. Heart Circ. Physiol. 2003 285 : H938 45.
14. Stelzner TJ, O'Brien RF, Yanagisawa M. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am. J. Physiol. 1992 262 : L614 20.
15. Everett AD, Le Cras TD, Xue C et al. eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow. Am. J. Physiol. Lung Cell Mol. Physiol. 1998 274 : L1058 65.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987 162 : 156 159.
17. Voelkel NF, Tuder RM. Cellular and molecular biology of vascular smooth muscle cells in pulmonary hypertension. Pulm. Pharmacol. Ther. 1997 10 : 231 241.
18. Fukunaga Y, Itoh H, Doi K et al. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 2001 158 : 113 119.
19. Matsuda Y, Hoshikawa Y, Ameshima S et al. Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats. Nihon Kokyuki Gakkai Zasshi 2005 43 : 283 288.
20. Hansmann G, Wagner RA, Schellong S et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator- activated receptor-gamma activation. Circulation 2007 115 : 1275 1284.
21. Crossno JT Jr., Garat CT, Reusch JE et al. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am. J. Physiol. Lung Cell Mol. Physiol. 2007 292 : L885 97.
22. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research 'work in progress'. Circulation 2000 102 : 2187 2191.
23. Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. 2004 61 : 227 237. (Pubitemid 38091763)
24. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998 391 : 82 6.
25. Alvarez Arroyo MV, Caramelo C, Angeles Castilla M et al. Role of vascular endothelial growth factor in the response to vessel injury. Kidney Int. Suppl. 1998 68 : S7 9.
26. Minchenko A, Bauer T, Salceda S et al. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab. Invest. 1994 71 : 374 379.
27. Shweiki D, Itin A, Soffer D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992 359 : 843 845.
28. Fujita M, Mason RJ, Cool C et al. Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression. J. Appl. Physiol. 2002 93 : 2162 2170.
29. Geiger R, Berger RM, Hess J et al. Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease. J. Pathol. 2000 191 : 202 207.
30. Hirose S, Hosoda Y, Furuya S et al. Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension. Pathol. Int. 2000 50 : 472 479.
31. Partovian C, Adnot S, Eddahibi S et al. Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am. J. Physiol. 1998 275 : H1948 56.
32. Partovian C, Adnot S, Raffestin B et al. Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am. J. Respir. Cell Mol. Biol. 2000 23 : 762 771.
33. Christou H, Yoshida A, Arthur V et al. Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 1998 18 : 768 776.
34. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J. Clin. Invest. 1995 95 : 1798 1807.
35. Campbell AI, Zhao Y, Sandhu R et al. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 2001 104 : 2242 2248.
36. Fried R, Meyrick B, Rabinovitch M et al. Polycythemia and the acute hypoxic response in awake rats following chronic hypoxia. J. Appl. Physiol. 1983 55 : 1167 1172.
37. Janssens SP, Thompson BT, Spence CR et al. Polycythemia and vascular remodeling in chronic hypoxic pulmonary hypertension in guinea pigs. J. Appl. Physiol. 1991 71 : 2218 2223.
38. Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am. J. Med. 2003 115 : S111 15.
39. Nolan JJ, Jones NP, Patwardhan R et al. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. Diabet. Med. 2000 17 : 287 294.
40. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab. Res. Rev. 2002 18 (Suppl. 2 S23 9.